Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYRRHINIL-INTEST is a herbal medicinal product developed by REPHA GmbH Biologische Arzneimittel, primarily indicated for the treatment of gastrointestinal disorders such as non-specific diarrhea, flatulence, and cramping. The formulation is a combination of three active botanical components: myrrh (Commiphora myrrha), coffee charcoal (Coffea arabica), and chamomile flower dry extract (Matricaria chamomilla). Myrrh acts as an anti-inflammatory and astringent agent; coffee charcoal serves as an adsorbent for toxins and metabolic products while also providing astringent properties; and chamomile extract offers spasmolytic and anti-inflammatory effects. In Germany, it is also utilized as a maintenance therapy for inflammatory bowel diseases, specifically ulcerative colitis, to prolong remission periods. It is currently being investigated in a Phase IV clinical trial for its efficacy and safety in patients with diarrhoea-predominant irritable bowel syndrome (IBS-D).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MYRRHINIL-INTEST (Repha).